



# INSTITUTIONAL BIOSAFETY COMMITTEE

---

UNIVERSITY *of* WASHINGTON

## Meeting Minutes

**Date:** Wednesday, February 20, 2019

**Time:** 10:00 AM – 12:00 PM

**Location:** Foege N130A

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
  2. H.D. “Toby” Bradshaw, Biology (*Plant Expert*)
  3. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
  4. Richard Grant, Washington National Primate Research Center
  5. Garry Hamilton (*Community Member*)
  6. David Koelle, Allergy and Infectious Diseases
  7. Stephen Libby, Laboratory Medicine (*IBC Chair*)
  8. Tina Rogers (*Community Member*)
  9. Jason Smith, Microbiology (*IBC Vice Chair*)
  10. Eric Stefansson, Environmental Health & Safety (*Biosafety Officer, Animal Containment Expert*)
  11. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

### Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present. Committee member updates were given, and a new ad hoc reviewer was introduced to the committee.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
  - The IBC Chair sought a motion to approve the minutes from the January 16, 2019 meeting.
  - A member made a motion to approve the January 16, 2019 minutes. Another member seconded the motion.
  - The committee voted unanimously to approve the January 16, 2019 meeting minutes.
4. **OLD BUSINESS:**
  - At the July 2018 meeting, Dr. Patel's BUA was approved pending a lab inspection. This is still pending.
  - At the September 2018 meeting, Dr. Greninger's BUA was approved pending a successful lab inspection. The BUA letter has been sent.
  - At the October 2018 meeting, Dr. Stuber's BUA was approved pending a lab inspection and room changes to the BUA letter. This is still pending.
  - At the November 2018 meeting, Dr. Bornfeldt's BUA was approved pending additions to the BUA letter. This is still pending.
  - At the November 2018 meeting, Dr. Steinmetz's BUA was approved pending a successful lab inspection. This is still pending.
  - At the January 2019 meeting, Dr. Noss's BUA was approved pending verification of third generation lentiviral vectors. This is still pending.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
  - a. Biosafety Officer Report
    - Dr. Dichek added a vivarium location for mice to the BUA *Gene Transfer in Cardiovascular Disease (Mice)*.
    - Dr. Gibran renewed the BUA *Gibran Laboratory – HMC R&T Surgery Inflammation*, approving in vitro use of human blood, tissue, body fluids, and cell lines.
    - Dr. Yu renewed the BUA *R&D of semiconductor polymer dots (Pdots) applied as fluorescent probes in life sciences*, approving in vitro use of human blood, tissue, body fluids, and cell lines.
    - Dr. Mao renewed the BUA *Fetal Exposure to Drugs*, approving in vitro use of human blood, tissue, body fluids, and cell lines, as well as recombinant or synthetic DNA/RNA (non-viral) enhanced gene delivery methods.
    - Dr. Adams Waldorf added new lab, cell sorting, and vivarium locations for their macaques to the BUA *Experimental Model for Chorioamnionitis and Preterm Labor*.
    - Dr. Yabuki renewed the BUA *Antibody Development*, approving in vitro use of human cells.

- Dr. Posner renewed the BUA *Point of Care HIV Viral Load Test*, approving in vitro use of Chlamydia trachomatis, Human immunodeficiency virus (HIV), and human blood, tissue, body fluids, and cell lines.
- Dr. Hoffman moved lab locations for the BUA *Microbiology of people with cystic fibrosis and other chronic infections*.
- Dr. Doulatov added a vivarium for previously approved agents in mice to the BUA *Hematopoiesis from cord blood and pluripotent stem cells*.
- Dr. Kreuzer became the new PI for the BUA *Preparation of cell cultures*, which uses non-human primate blood, tissue, body fluids, and cell lines in vitro.
- Dr. Kreuzer became the new PI for the BUA *Propagation of Sindbis Virus*, which uses Sindbis virus and non-human primate blood, tissue, body fluids, and cell lines in vitro.
- Dr. Kreuzer's became the new PI for the BUA *RNA Analysis of Eastern Equine Encephalitis Virus and Venezuelan Equine Encephalitis Virus: BSL3 (PHAA 70788)*. This project was approved by the committee. However, work cannot begin until CDC approval is granted and additional requirements are completed. This project works with all virus strains at BSL 3.
- Dr. Miller added vivariums to the BUA *Role of the phoP Regulon and Salmonella Virulence/Regulation of Salmonella Invasion of Epithelia/SPI2*.
- Dr. Chavkin added a room for use of previously approved agents to the BUA *Chavkin: Mice*.
- Dr. Hu added vivariums for their macaques to the three BUAs: *HIVRAD: Core B: Virology/Immunology; Glycan modification, CD4 independence, and Env Immunogenicity*; and, *Virus-like particles (VLP) with stabilized trimeric envelope (ENV) for prime-boost immunization*.
- Dr. Mougous added in vitro use of human iPS cells, Campylobacter jejuni, and Mycobacterium abscessus to the BUA *Type VI secretion-dependent interbacterial interactions*. This change also added a cell analysis facility.
- Dr. Bruce renewed the BUA *Mapping Protein-Protein Interaction Network In Human Serum, Sputum, Cancer Cells, and Bacterial Cells*, approving in vitro use of Acinetobacter baumannii, Klebsiella pneumonia, Mycobacterium smegmatis, Pseudomonas aeruginosa, and Salmonella Typhimurium.
- Dr. Pham's new BUA *Sample Processing for Clinical Research Studies* was approved, permitting in vitro use of human blood, tissue, body fluids, and cell lines.
- Dr. Thummel renewed the BUA *CYP3A Regulation*, allowing in vitro use of human blood, tissue, body fluids, and cell lines.
- The IBC Chair sought a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

**6. DURC REPORT:** The Dual Use Research of Concern Institutional Review Entity (DURC IRE) did not meet this month because there were no applications to review.

## **7. SECTION III-D AMENDMENTS**

- a. Plymate, Stephen, change, *Mechanisms of transition to castrate resistant prostate cancer*
  - The assigned IBC Primary Reviewer presented the Primary Review.

- This project change is to add the use of 2<sup>nd</sup> generation lentiviral vectors for work in vitro and in mice. The lab was previously approved for use of 3<sup>rd</sup> generation lentiviral vector work.
  - The lab has not yet been set up. The investigator will be moving to a new location within the next few months. The biosafety officer will inspect the lab once the lab is ready.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Plymate pending a successful lab inspection.
  - The Committee voted unanimously to approve the draft BUA for Dr. Plymate pending a successful lab inspection.
- b.** Ruohola-Baker, Hannele, change, *microRNA Function in Human Embryonic Stem Cells*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This change adds the use of non-human primate cells transduced with lentiviral vectors. The lab is already approved for use of human and mouse cells transduced with lentiviral vectors.
  - The lab was recently inspected, so a new lab inspection was not required for this change.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ruohola-Baker.
  - The Committee voted unanimously to approve the draft BUA for Dr. Ruohola-Baker.

## 8. INDIVIDUAL PROJECT REVIEWS

- c.** Adams Waldorf, Kristina, renewal, *Experimental Model of Viral-Induced Brain Injury*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This research uses recombinant vesicular stomatitis virus expressing Zika virus envelope protein in vitro and in vivo (administered to non-human primates). It also uses Zika virus in macaques. It strives to determine the effects of various infectious diseases on pregnancy and the fetus with the goal of developing vaccines and therapeutics to prevent injury.
  - Processing of non-human primate tissues and fluids and work with viruses at BSL-2 with BSL-3 practices present the greatest risk to laboratory personnel.
  - A subcommittee will be formed to evaluate the appropriate biosafety containment level for Japanese Encephalitis virus (JEV). The committee decided that there is no issue using HIV at BSL 2 with 3 practices. West Nile use at BSL 2 with 3 practices was based on a previous risk assessment by the IBC, and will be reviewed.
  - A lab inspection needs to be completed to approve BSL2 with 3 practices.
  - All of the required trainings have been completed.
  - The PI will need to remove JEV from their IACUC protocol to approve before the subcommittee has made a determination regarding the proper biosafety containment level.
  - The draft BUA letter was shown.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Adams-Waldorf pending a successful lab inspection and the removal of JEV.
  - The Committee voted unanimously to approve the draft BUA for Dr. Adams-Waldorf pending a successful lab inspection and the removal of JEV from the BUA.
- d. Berg, Celeste, renewal, *Regulation of tubulogenesis in the Drosophila ovary*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This project uses E. coli-grown recombinant DNA plasmids containing various genes to study air exchange tubes that arise during ovary development in fruit flies.
  - The lab inspection found that the location is not appropriate for lab use due to carpeting, so the PI requires a new room. Negative airflow is not required.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Berg pending a successful lab inspection.
  - The Committee voted unanimously to approve the draft BUA for Dr. Berg pending the correction of deficiencies identified in the lab inspection.
- e. Chait, Alan, renewal, *Lipoproteins, Inflammation and Atherosclerosis*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This project examines how the function of the high-density lipoprotein, ApoA1, changes under conditions associated with cardiovascular disease. Lentiviral vectors are used for work in vitro and in mice. Adeno-associated viral vectors (adenovirus free) are used for work in vitro.
  - The lab was recently inspected following a relocation, so a new lab inspection was not required for this renewal.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chait.
  - The Committee voted unanimously to approve the draft BUA for Dr. Chait.
- f. Chamberlain, Jeffrey, renewal, *Gene Therapy for Neuromuscular Disorders*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This project's goal is to develop a treatment or cure for muscular dystrophy by delivering new therapeutic genes.
  - The PI declared that the greatest risk to laboratory personnel involves the use of human cell lines.
  - Third-generation lentiviral vectors and adeno-associated viral vectors (AAV) are used in vitro and in mice.
  - The lab recently acquired additional spaces, and requires a final lab inspection.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chamberlain pending a final lab inspection.
  - The Committee voted unanimously to approve the draft BUA for Dr. Chamberlain pending a final lab inspection.

- g. Crispe, Ian, renewal, *Novel AAV-based tools for liver immunology AND Innate immune response to hepatocyte death AND sessile Kupffer cells in liver tolerance*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This research uses Plasmodium species (malaria), recombinant adeno-associated viral vectors, and lipid enhanced DNA delivery to reveal how cells and molecules of the liver and the greater immune system work together to fight hepatitis virus infection, and how they respond to the death of hepatocytes.
  - An IBC member inquired if the investigator is obtaining Plasmodium falciparum from a nearby Seattle biotech company and transporting it back to his lab at UW. The biosafety officer will check with the PI about where they are obtaining P. falciparum. If this project does involve transporting biohazardous materials, the biosafety officer will ensure that these are transported in a leak-proof secondary container and that all other transporting procedures (including using only UW-owned and operated vehicles) outlined in the Biosafety Manual are followed.
  - Work with human liver slices and Hepatitis B and C present the greatest biohazardous risk to laboratory personnel.
  - The lab requires a successful lab inspection.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Crispe pending a successful lab inspection, clarification about whether malaria sporozoite transport is required and if university procedures are being followed.
  - The Committee voted unanimously to approve the draft BUA for Dr. Crispe pending a successful lab inspection and clarification about whether malaria sporozoite transport is required and if university procedures are being followed.
- h. Duan, Zhijun, new, *Development of Cell Growth Switch*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This lab focuses on deciphering the structure-function relationship of the 3D genome to understand the molecular mechanisms underlying human development and tumorigenesis.
  - The greatest biohazardous risks involve recombinant lentiviral vectors and human cell lines.
  - The lab was inspected and no deficiencies were identified.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Duan.
  - The Committee voted unanimously to approve the draft BUA for Dr. Duan.
- i. Gale, Michael, renewal, *The Host Response to Virus Infection*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This lab aims to understand how viral and host factors impact innate immune defenses to determine the outcome of virus infection.
  - The many viruses used in this project present the greatest biohazardous risks to laboratory personnel.
  - A list of influenza strains used in this lab have been provided along with the BUA application.
  - The lab was inspected and no deficiencies were identified.

- All of the required trainings have been completed.
- Occupational health consultation is required before laboratory personnel begin any work with hepatitis B, influenza virus, LCMV WE strain, poliovirus, vaccinia virus, and Zika virus.
- Japanese encephalitis virus (JEV) needs to be removed from the IACUC protocol in order to be approved. A JEV subcommittee will review the appropriate BSL for this agent at March 20 IBC meeting.
- A previous IBC subcommittee decided that LCMV WE strain is to be contained at BSL 2 with 3 practices. The IBC will verify this decision.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Gale pending the removal of JEV from the BUA and verification of LCMV (WE) strain containment.
- The Committee voted unanimously to approve the draft BUA for Dr. Gale pending the removal of JEV from the BUA and verification of LCMV (WE) strain containment.

j. Liao, John, new, *Immune responses in gynecologic cancers*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This research focuses on developing diagnostic, preventative, and treatment strategies to combat gynecologic cancers. Work includes transfecting human cells with recombinant plasmid DNA for protein expression.
- The greatest risk to laboratory personnel is BBP exposure from human blood or tissue.
- Non-replicating oncogenes are being used in plasmids.
- The lab requires a complete lab inspection.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Liao pending a completed lab inspection and BUA changes.
- The Committee voted unanimously to approve the draft BUA for Dr. Liao pending a complete lab inspection and changes to the BUA.

k. Lieber, Andre, renewal, *Stem Cell and Gene Therapy of Cancer and Hematological Diseases*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This research includes work in vitro and in vivo with adenoviral vectors and mouse models to deliver therapeutic genes into tumors or stem cells.
- The greatest biohazardous risk to laboratory personnel involves work with human and non-human primate tissues and primary cells.
- The lab inspection is scheduled for next week.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Lieber pending changes to BUA.
- The Committee voted unanimously to approve the draft BUA for Dr. Lieber pending a successful lab inspection and updates to the BUA.

l. Nahmani, Marc, new, *Structure and Function of Neuronal Microcircuits*

- The assigned IBC Primary Reviewer presented the Primary Review.

- This lab uses recombinant plasmids and viral vectors to try to understand the mechanisms responsible for initiating and ending ‘critical periods’ in the brain when the neurons and ‘plastic,’ allowing them to recover from injury and enhance our ability to learn new skills and tasks.
  - This is the first PI at UW Tacoma that has required review by the UW IBC.
  - The lab requires a successful lab inspection.
  - The required trainings have yet to be completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Nahmani pending a successful lab inspection and the verification of 3<sup>rd</sup> generation lentiviral vectors.
  - The Committee voted unanimously to approve the draft BUA for Dr. Nahmani pending a successful lab inspection and the verification of 3<sup>rd</sup> generation lentiviral vectors.
- m. Polyak, Stephen, change, *Virus-Host Interactions in Cell Culture*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This change adds Pichinde Arenavirus (PICV) and Murine Leukemia Virus based pseudoviruses.
  - PICV is listed on the BUA letter at BSL2, it’s the lowest containment level, even though the PI will be working with it at BSL 2 with 3 practices.
  - The lab was recently inspected, so a new lab inspection was not required for this change.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Polyak.
  - The Committee voted unanimously to approve the draft BUA for Dr. Polyak. One member abstained from the vote because she had left the room during the review.
- n. Sullivan, Jane, renewal, *Cellular and Molecular Mechanisms of Synaptic Transmission*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This research strives to understand synaptic communication in normal and diseased neurons in vitro by introducing a variety of genes (reporters and functional variants) into murine neurons and other cell cultures. Lentiviral vectors, Semliki Forest virus, and herpes simplex virus are all used in vitro.
  - The lab was inspected and no deficiencies were identified.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sullivan.
  - The Committee voted unanimously to approve the draft BUA for Dr. Sullivan.
- o. Theberge, Ashleigh, renewal, *Studying cell signaling and cell-microenvironment interactions with new analytical tools*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This project uses human cell lines, bacteria, and fungi to understand how chemical interactions between different cell types within an organ and/or with microbes may contribute to disease processes in the prostate, kidney, lung, and testis.
  - The lab was inspected and no deficiencies were identified.



- All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Theberge.
  - The Committee voted unanimously to approve the draft BUA for Dr. Theberge.
- p. Zhang, Miqin, renewal, *Molecular MR Imaging of Tumors*
- The assigned IBC Primary Reviewer presented the Primary Review.
  - This lab develops nanoparticle (NP) systems that can differentiate normal from tumor tissue using MRI and may be used for cancer treatment applications. NPs are tested in vitro and in vivo in mice and rats.
  - The greatest biohazardous risk to laboratory personnel is the use of human cancer cells and oncogenes. No oncogenes are in amphotropic inserts.
  - The lab was inspected and no deficiencies were identified.
  - All of the required trainings have been completed.
  - The draft BUA letter was shown.
  - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Zhang.
  - The Committee voted unanimously to approve the draft BUA for Dr. Zhang.

## 9. SUBCOMMITTEE REPORTS:

- q. Colby, Lesley, renewal, *Department of Comparative Medicine SLU 3.1 BSL3/ABSL3 Facility*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
  - This renewal application is for the continued operators of the BSL3-ABSL3 core facility at SLU 3.1. This application is for facility operation only. PIs who wish to conduct research in the facility are required to submit a separate BUA application for IBC review.
  - The draft BUA letter was shown.
  - A member made a motion to approve the draft BUA letter for Dr. Colby. Another member seconded the motion.
  - The Committee voted unanimously to approve the draft BUA for Dr. Colby.
- r. Disis, Mary, renewal, *A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients with Breast Cancer*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
  - The primary objectives are to assess the safety of a multi-antigen vaccine in participants with breast cancer who are in remission, and to determine the immunogenicity of specific vaccine doses.
  - The greatest biohazardous risk involves exposure through a needle stick during manufacturing, preparation, or administration of the vaccine.
  - There have been no adverse events reported in the past three years.
  - The draft BUA letter was shown.
  - A member made a motion to approve the draft BUA letter for Dr. Disis. Another member seconded the motion.
  - The Committee voted unanimously to approve the draft BUA for Dr. Disis.

- s. Ujjani, Chaitra, new, *A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucef as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)*
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
  - This study evaluates the safety and efficacy of an engineered autologous T-cell immunotherapy as a first-line therapy in adults with high-risk large B cell lymphoma.
  - All retroviral vector samples tested have been negative for replication competent retrovirus (RCR), limiting biohazardous issues to needle sticks.
  - The draft BUA letter was shown.
  - A member made a motion to approve the draft BUA letter for Dr. Ujjani. Another member seconded the motion.
  - The Committee voted unanimously to approve the draft BUA for Dr. Ujjani.
- t. Wong, Kit, new, *An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors*
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
  - This proposed work is to test an oncolytic herpes simplex virus (oHSV) to potentially improve anti-tumor immune responses.
  - Needle sticks during preparation or injection of the study subject presents the greatest risk to hospital staff.
  - Occupational Health will verify that standard BSL2 PPE is in place for clinical staff.
  - The draft BUA letter was shown.
  - A member made a motion to approve the draft BUA letter for Dr. Wong. Another member seconded the motion.
  - The Committee voted unanimously to approve the draft BUA for Dr. Wong.

#### 10. FOR YOUR INFORMATION:

- **Amended September IBC Meeting Minutes:** The September 2018 IBC meeting minutes are being revised, and will be reposted to the UW website upon approval of the revision.
- **IBC Charter Revision:** IBC committee membership terms have been changed from three years to two years to reflect a new UW School of Medicine policy for all standing committees.
- **NIH Incident Reports:**
  - An individual accidentally stuck their thumb with a needle that was used to administer fluids to a non-human primate (NHP) that had been inoculated with HSIV. The individual was wearing appropriate personal protective equipment (PPE) and post exposure procedures were correctly followed. The incident was investigated and the SOP for administering fluids will be revised to include additional procedures to reduce the potential risk of a sharps injury. This incident was reported to the NIH.
  - A NHP scratched an employee on the hand through their gloves while the person was transferring NHPs from individual cages to shared caging. The NHPs had been inoculated with SHIV. The person was wearing appropriate PPE. Post exposure procedures were correctly followed. The employee is undergoing additional training. This incident was reported to the NIH.

**11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.

**12. MEETING ADJOURNED AT APPROXIMATELY 12:07 P.M.**